DelveInsight has launched a new report on “Hypoparathyroidism – Market Insights, Epidemiology, and Market Forecast-2032”.
Some of the key facts of the Hypoparathyroidism Market Report:
As per a study, the prevalence of hypoparathyroidism is an estimated 37 per 100 000 person-years in the United States. Estimates of prevalence and incidence of hypoparathyroidism are currently lacking in most other countries.
A study reported that Primary hyperparathyroidism (PHPT) occurs in an estimated 0.2% to 0.5% of the US population. There are approximately 100,000 new cases in the United States each year and approximately 80-85% of cases of PHPT are caused by a single parathyroid adenoma.
Key benefits of the report:
Hypoparathyroidism market report covers a descriptive overview and comprehensive insight of the Hypoparathyroidism Epidemiology and Hypoparathyroidism market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Hypoparathyroidism market report provides insights on the current and emerging therapies.
Hypoparathyroidism market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Hypoparathyroidism market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hypoparathyroidism market.
Hypoparathyroidism is a rare endocrine disorder characterized by low calcium and high phosphate levels, in the setting of a simultaneously low or inappropriately normal PTH level. Hypoparathyroidism has been classified as an orphan disease in the United States and by the European Commission.
People living with hypoparathyroidism experience a diverse range of physical, mental, cognitive and emotional symptoms. They often suffer debilitating symptoms and the condition can severely impact the quality of life and overall productivity, including the ability to work and perform household activities.
The dynamics of the Hypoparathyroidism market are anticipated to change in the coming years owing to the expected launch of emerging therapies by companies such as Entera Bio, Ascendis Pharma, and others during the forecasted period 2019-2032.
Learn more by requesting for sample @ Hypoparathyroidism Market Landscape
Hypoparathyroidism Pipeline Therapies and Key Companies
PTH (1-34): Entera Bio
TransCon PTH: Ascendis Pharma
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Hypoparathyroidism Patient Share (%) Overview at a Glance
5. Hypoparathyroidism Market Overview at a Glance
6. Hypoparathyroidism Disease Background and Overview
7. Hypoparathyroidism Epidemiology and Patient Population
8. Country-Specific Patient Population of Hypoparathyroidism
9. Hypoparathyroidism Current Treatment and Medical Practices
10. Unmet Needs
11. Hypoparathyroidism Emerging Therapies
12. Hypoparathyroidism Market Outlook
13. Country-Wise Hypoparathyroidism Market Analysis (20198–2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
18. Hypoparathyroidism Report Methodology
19. DelveInsight Capabilities
21. About DelveInsight
Click here to read more about Hypoparathyroidism Market Outlook 2032.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States